Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ruggenenti, P.
Right arrow Articles by Remuzzi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruggenenti, P.
Right arrow Articles by Remuzzi, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 1900-1902
© 2000 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment?

Piero Ruggenenti1,2 and Giuseppe Remuzzi,1,2

1 Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases ‘Aldo e Cele Daccò’ Villa Camozzi, Ranica and 2 Unit of Nephrology, Ospedali Riuniti, Azienda Ospedaliera, Bergamo, Italy

Introduction

Diabetic nephropathy is a syndrome of albuminuria, declining glomerular filtration rate (GFR), arterial hypertension, and increased cardiovascular risk that affects 20–40% of type 1 (insulin-dependent) and type 2 (non insulin dependent) diabetic patients [1–3]. Diabetics, mostly type 2, account for about one third of all patients requiring chronic renal replacement therapy in western countries. Indeed, type 2 diabetics with end-stage renal disease (ESRD) are rapidly increasing because of the continuing increase in the prevalence of type 2 diabetes and the progressively declining mortality rate from cardiovascular causes. The costs associated with management of the disease (in 1996, $4.6 billion in the United States alone) are increasing in proportion and will soon become unbearable for most western countries. High mortality, costs, and decreased quality of life associated with chronic renal replacement therapy, have motivated the search for the causes and the possible treatments that might effectively delay . . . [Full Text of this Article]

Overt nephropathy: the role of tertiary prevention

Incipient nephropathy: the role of secondary prevention

Primary prevention of diabetic nephropathy: a target for the third millennium

Conclusions

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
H. Kramer and M. E. Molitch
Screening for Kidney Disease in Adults With Diabetes
Diabetes Care, July 1, 2005; 28(7): 1813 - 1816.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Coppelli, R. Giannarelli, F. Vistoli, S. Del Prato, G. Rizzo, F. Mosca, U. Boggi, and P. Marchetti
The Beneficial Effects of Pancreas Transplant Alone on Diabetic Nephropathy
Diabetes Care, June 1, 2005; 28(6): 1366 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
B. F. Schrijvers, A. S. De Vriese, J. Van de Voorde, R. Rasch, N. H. Lameire, and A. Flyvbjerg
Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes
Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1092 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. Benigni, C. Zoja, D. Corna, C. Zatelli, S. Conti, M. Campana, E. Gagliardini, D. Rottoli, C. Zanchi, M. Abbate, et al.
Add-On Anti-TGF-{beta} Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat
J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1816 - 1824.
[Abstract] [Full Text] [PDF]

Home page
 JRSMHome page
M. A J Devonald and F. E Karet
Targeting the renin-angiotensin system in patients with renal disease
J R Soc Med, January 8, 2002; 95(8): 391 - 397.
[Full Text] [PDF]